News & Events » 2008

Dec 2008

Signum Biosciences is proud to announce the appointment of Dr. Jeffrey Cummings to its scientific advisory board. Dr. Cummings is a world leader in the development of new treatments for neurodegenerative disorders. See Dr. Cummings Bio

Nov 2008

Dr. Estelle Sontag et al. show down-regulation of PP2A Bα subunit expression correlates with enhanced tau phosphorylation, highlighting the critical role of PP2A methylation. A link between impaired methylation and NFT formation in Alzheimer's Disease was first proposed by co-founder Dr. Jeffry Stock. Learn more

Sept 2008

Signum Biosciences is proud to announce the appointment of Dr. Khalid Iqbal to its scientific advisory board. Dr. Iqbal is a world leader in the field of neurodegenerative disorders. See Dr. Iqbal's Bio

Jul 2008

Signum Biosciences awarded a phase I Small Business Innovation Research (SBIR) grant ($298K) from the NIAID to study our GPM compounds as a “Novel class of non steroidal anti-inflammatories”.

Signum Biosciences has entered into a joint development license and commercialization agreement with Rohto Pharmaceutical Co., Ltd, for the development and commercialization of our proprietary technologies in the Japanese market. See the Press Release

Jun 2008

Kunio Yamada of Rohto Pharmaceuticals joins Signum’s Board of Directors.

Signum is granted INCI approval from the Cosmetic, Toiletry and Fragrance Association (CTFA) for Arazine™ as well as STMs as a new class of cosmetic ingredients.

Signum Biosciences and Dr. Jose Fernandez, PhD, awarded a research fellowship award from NJCST.

Apr 2008
Signum opens Series A-3 financing round for $3 million.

Collaborative research effort at Princeton University (including Dr. Jeffry Stock) determines the “Structural mechanism of demethylation and inactivation of protein phosphatase 2A”. (Published in Cell)

Mar 2008
Signum Biosciences expands: To accommodate our companies rapid growth and increased work force, we have relocated within the Princeton Corporate Plaza to a larger facility with increased laboratory and office space.

Mar 2008
Signum Biosciences research findings that “Topical AFC inhibits mouse skin inflammation, and unlike dexamethasone, its effects are restricted to the application site” are published in the Journal of Investigative Dermatology.